Dermapharm AG

Merck KGaA says it is still on track to hit its healthcare sales target of around €2bn for 2020 now that the multiple sclerosis drug Mavenclad and its fertility products have weathered the impact of

The sale of Merck KGaA ’s allergy immunotherapy unit, Allergopharma, will not only improve the focus and reduce the debt pile of the big pharma, it will also add a new international business to the a

Dermapharm Boosts Supplements Business With Acquisition German manufacturer Dermapharm AG is looking to boost its presence in the European dietary supplements market with the purchase of a majority

GSK Refreshes Otriven Line GlaxoSmithKline PLC (GSK) is investing in its Otriven range of nasal sprays this Spring with a sports-themed online campaign for Otri Allergie and a new xylometazoline